| Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma P Strati, S Ahmed, F Furqan, LE Fayad, HJ Lee, SP Iyer, R Nair, ... Blood, The Journal of the American Society of Hematology 137 (23), 3272-3276, 2021 | 124 | 2021 |
| Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma P Strati, LJ Nastoupil, J Westin, LE Fayad, S Ahmed, NH Fowler, ... Blood advances 4 (16), 3943-3951, 2020 | 75 | 2020 |
| Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy A Al Zaki, L Feng, G Watson, SA Ahmed, H Mistry, LJ Nastoupil, ... Blood Advances 6 (9), 2867-2871, 2022 | 29 | 2022 |
| Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). P Strati, F Furqan, J Westin, L Fayad, S Ahmed, HJ Lee, SP Iyer, R Nair, ... Journal of Clinical Oncology 38 (15_suppl), 8011-8011, 2020 | 14 | 2020 |
| Managing cancer survivorship issues E Mullen, H Mistry The Journal for Nurse Practitioners 14 (4), 337-343, 2018 | 14 | 2018 |
| Journal of the International Society of Sports Nutrition: a new era begins RB Kreider Journal of the International Society of Sports Nutrition 4 (1), 1, 2007 | 12* | 2007 |
| Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy P Strati, AP Jallouk, R Sun, J Choi, K Das, HJ Cherng, S Ahmed, HJ Lee, ... Leukemia 36 (11), 2669-2677, 2022 | 9 | 2022 |
| Toxicity management: Development of a novel and immune-mediated adverse events algorithm HE Mistry Number 2/April 2017 21 (2), 53-59, 2017 | 7 | 2017 |
| Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response AP Jallouk, S Gouni, J Westin, L Feng, H Mistry, RE Steiner, J James, ... Haematologica 108 (4), 1163, 2023 | 6 | 2023 |
| Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma CY Cheah, HE Mistry, S Konoplev, NH Fowler Leukemia & Lymphoma 57 (8), 1974-1976, 2016 | 4 | 2016 |
| Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides E Fountain, H Mistry, P Jain, M Duvic, N Fowler Leukemia & Lymphoma 60 (4), 1079-1082, 2019 | 2 | 2019 |
| Comorbidities associated with early mortality after CD19 CAR-T cell therapy K Tang, R Khwaja, L Feng, P Strati, RE Steiner, R Nair, CR Flowers, ... Blood 140 (Supplement 1), 4684-4685, 2022 | 1 | 2022 |
| Immune-Mediated Therapies in Lymphoma SG Forbes, HE Mistry Seminars in Oncology Nursing 35 (5), 150925, 2019 | 1 | 2019 |
| Concordance analysis between practice and algorithm recommendations for cardiac screening in a cohort of high-risk lymphoma survivors. WS Thoman, KR Gilmore, PH Chapman, W Bi, H Mistry, E Mullen, ... JCO Oncology Practice 19 (11_suppl), 498-498, 2023 | | 2023 |
| The MD Anderson Symptom Inventory (MDASI) survey discloses persistent moderate to high-level symptoms in cancer survivors K Gilmore, P Chapman, J Rollins, SH Lee-Kim, J Robinson, E Mullen, ... Cancer Research 83 (7_Supplement), 4367-4367, 2023 | | 2023 |
| Integration of patient-reported outcomes into survivorship care. KR Gilmore, PH Chapman, J Rollins, S Lee-Kim, J Robinson, E Mullen, ... Journal of Clinical Oncology 40 (28_suppl), 271-271, 2022 | | 2022 |
| Biomarker Jeopardy SE Kurtin, A Henglefelt, H Mistry Journal of the Advanced Practitioner in Oncology 13 (3), 292, 2022 | | 2022 |
| Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy A Al Zaki, JR Westin, G Watson, L Feng, S Ahmed, H Mistry, L Nastoupil, ... Blood 138, 3870, 2021 | | 2021 |
| Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion S Gouni, JR Westin, H Mistry, RE Steiner, J James, S Parmar, M Noorani, ... Blood 138, 1740, 2021 | | 2021 |
| Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL) S Ahmed, P Strati, L Fayad, F Hagemeister, HJ Lee, SP Iyer, R Nair, ... 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021 | | 2021 |
